SCHEMBL21887777

SCHEMBL21887777

CCOC(=O)c1cnn2c(N(C)Cc3ccc(OC)cc3)cc(Nc3ccccc3OC)nc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ NPSR1 Q6W5P4 3/20 0.44
▸ TSHR P16473 2/20 0.44
▸ USP2 O75604 1/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ ALDH1A1 P00352 4/20 0.42
▸ KDM4E B2RXH2 4/20 0.42
▸ HPGD P15428 3/20 0.42
▸ HSD17B10 Q99714 3/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ POLB P06746 1/20 0.42
▸ LMNA P02545 2/20 0.41
▸ TYK2 P29597 2/20 0.41
▸ JAK2 O60674 1/20 0.41
▸ JAK1 P23458 1/20 0.41
▸ JAK3 P52333 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ STAT3 P40763 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21887781 0.95 NPSR1 (0.43) MAPTSMN1; SMN2NPSR1TSHRUSP2
SCHEMBL21887375 0.92 KDM4E (0.42) MAPTSMN1; SMN2NPSR1TSHRALDH1A1
SCHEMBL21811164 0.91 AKR1C3 (0.46) MAPTSMN1; SMN2NPSR1ALDH1A1KDM4E
SCHEMBL21887378 0.88 KCNH2 (0.44) MAPTNPSR1ALDH1A1KDM4EPOLB
SCHEMBL22092637 0.87 KDM4E (0.41) MAPTSMN1; SMN2NPSR1TSHRALDH1A1
SCHEMBL31245714 0.85 TYK2 (0.54) TYK2JAK2JAK1STAT3
SCHEMBL22092677 0.84 TYK2 (0.44) MAPTSMN1; SMN2NPSR1TSHRALDH1A1
SCHEMBL30349340 0.84 ADORA3 (0.48) MAPTSMN1; SMN2NPSR1TSHRUSP2
SCHEMBL24961730 0.82 MEN1 (0.43) MAPTSMN1; SMN2NPSR1TSHRALDH1A1
SCHEMBL21887372 0.82 TDP1 (0.44) MAPTNPSR1TSHRALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11891400-B2 Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus ELI LILLY AND COMPANY (US) 2024-02-06 — — US disclosed
EP-3849981-B1 PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS LILLY CO ELI (US) 2023-02-01 — — EP disclosed
EP-3849981-B1 PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS LILLY CO ELI (US) 2023-02-01 — — EP disclosed
US-20210188861-A1 PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS ELI LILLY AND COMPANY 2021-06-24 — — US disclosed
US-20210188861-A1 PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS ELI LILLY AND COMPANY 2021-06-24 — — US disclosed
WO-2020055636-A1 PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS ELI LILLY AND COMPANY (US) 2020-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11891400-B2 Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus SSB, TPMT, SPHK1 MAPT 4226/4885SMN1; SMN2 4790/4885NPSR1 1148/4885
US-20210188861-A1 PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS SSB, TPMT, SPHK1 MAPT 4226/4885SMN1; SMN2 4790/4885NPSR1 1148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback